Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Aliment Pharmacol Ther ; 16(8): 1529-38, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12182753

RESUMO

BACKGROUND: Percutaneous ethanol injection and hepatic resection are the most widely used curative therapeutic options for patients with compensated liver disease and small hepatocellular carcinoma. AIM: To compare percutaneous ethanol injection and hepatic resection in a selected group of consecutive French patients with a single hepatocellular carcinoma, smaller than or equal to 50 mm, in terms of survival, recurrence rate of malignancy and direct costs. METHODS: The analysis of two contemporary cohorts of Child-Pugh A or B patients with a single hepatocellular carcinoma of < or = 50 mm treated by percutaneous ethanol injection (n=55) or hepatic resection (n=50). RESULTS: Long-term survival was not significantly different between the two groups when the size of hepatocellular carcinoma was less than 30 mm. However, the survival of patients with hepatocellular carcinoma larger than 30 mm was higher after hepatic resection than after percutaneous ethanol injection (P=0.044). The cumulative direct costs were significantly higher in patients treated by hepatic resection than in those treated by percutaneous ethanol injection regardless of the tumour size. The calculated costs per month of survival in patients treated with percutaneous ethanol injection and hepatic resection were 999 vs. 3865 euros, respectively (P < 0.001). CONCLUSIONS: Percutaneous ethanol injection is more cost effective than hepatic resection in patients with a single hepatocellular carcinoma smaller than 30 mm. However, in patients with a larger tumour, long-term survival is higher after hepatic resection.


Assuntos
Antineoplásicos/administração & dosagem , Carcinoma Hepatocelular/terapia , Etanol/administração & dosagem , Custos de Cuidados de Saúde , Hepatectomia/métodos , Neoplasias Hepáticas/terapia , Idoso , Carcinoma Hepatocelular/economia , Carcinoma Hepatocelular/mortalidade , Estudos de Casos e Controles , Análise Custo-Benefício , Feminino , Seguimentos , França , Hepatectomia/efeitos adversos , Hepatectomia/economia , Humanos , Injeções Intralesionais , Tempo de Internação , Neoplasias Hepáticas/economia , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento
2.
J Radiol ; 77(1): 45-8, 1996 Jan.
Artigo em Francês | MEDLINE | ID: mdl-8815225

RESUMO

Primary lymphomas rarely affect the heart. The myocardial disease is usually latent and the diagnosis is based on post mortem observations. The cardiac symptoms do not reveal the disease and symptomatology is not specific. Our observation shows the complementarity of non invasive techniques, for a better screening of cardiac tumoral forms. Although echocardiography is the main examination, CT scan provides a detection of infiltrative forms and of extracardiac extension. Concurrently, MRI remains the method of choice to display beginning infiltrative forms, revealed by pericardial effusion in AIDS disease.


Assuntos
Neoplasias Cardíacas/diagnóstico por imagem , Linfoma Relacionado a AIDS/diagnóstico por imagem , Linfoma não Hodgkin/diagnóstico por imagem , Idoso , Ecocardiografia , Humanos , Masculino , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...